ADOCIA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.45 EUR | +0.48% |
|
-4.74% | -26.78% |
| Mar. 22 | Adocia: announces fund-raising | CF |
| Mar. 21 | Adocia SA announced that it expects to receive ?2 million in funding | CI |
| Sales 2023 * | 18.7M 19.92M | Sales 2024 * | 50M 53.26M | Capitalization | 119M 127M |
|---|---|---|---|---|---|
| Net income 2023 * | 14M 14.91M | Net income 2024 * | 26M 27.7M | EV / Sales 2023 * | 6.54 x |
| Net Debt 2023 * | 3.3M 3.52M | Net cash position 2024 * | 22.5M 23.97M | EV / Sales 2024 * | 1.93 x |
| P/E ratio 2023 * |
4.12
x | P/E ratio 2024 * |
2.27
x | Employees | 97 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.08% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.48% | ||
| 1 week | -4.74% | ||
| Current month | -3.54% | ||
| 1 month | -13.24% | ||
| 3 months | -18.75% | ||
| 6 months | +16.39% | ||
| Current year | -26.78% |
1 week
8.20
9.09
1 month
8.2010.70
Current year
8.2012.40
1 year
2.7616.16
3 years
2.7516.16
5 years
2.7522.60
10 years
2.7594.24
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Soula
FOU | Founder | 53 | 05-12-15 |
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director of Finance/CFO | - | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gérard Soula
FOU | Founder | 78 | 05-12-15 |
| Director/Board Member | 67 | 21-05-20 | |
| Director/Board Member | 58 | 13-06-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 8.45 | +0.48% | 55,041 |
| 24-04-18 | 8.41 | -1.06% | 59,515 |
| 24-04-17 | 8.5 | -1.96% | 64,962 |
| 24-04-16 | 8.67 | -1.70% | 60,137 |
| 24-04-15 | 8.82 | -0.56% | 42,064 |
Real-time Euronext Paris, April 19, 2024 at 11:35 am EDT
More quotes
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.
At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.45
EUR
Average target price
9.7
EUR
Spread / Average Target
+14.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.78% | 126M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- ADOC Stock
